Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Psoriasis
Interventions
DRUG

"Secukinumab Cosentyx TM"

"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY